Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Chinese Patent Office
Medtronic
Merck
Cerilliant
Mallinckrodt
Deloitte
AstraZeneca
Fuji

Generated: July 23, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022065

« Back to Dashboard

NDA 022065 describes IXEMPRA KIT, which is a drug marketed by R-pharm Us Llc and is included in one NDA. It is available from one supplier. There are six patents protecting this drug and one Paragraph IV challenge. Additional details are available on the IXEMPRA KIT profile page.

The generic ingredient in IXEMPRA KIT is ixabepilone. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the ixabepilone profile page.
Summary for 022065
Tradename:IXEMPRA KIT
Applicant:R-pharm Us Llc
Ingredient:ixabepilone
Patents:6
Formulation / Manufacturing:see details
Generic Entry Opportunity Date for 022065
Generic Entry Date for 022065*:
Constraining patent/regulatory exclusivity:
Dosage::
INJECTABLE;IV (INFUSION)

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Suppliers and Packaging for NDA: 022065
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
IXEMPRA KIT ixabepilone INJECTABLE;IV (INFUSION) 022065 NDA R-Pharm US Operating, LLC 70020-1910 N 70020-1910-1
IXEMPRA KIT ixabepilone INJECTABLE;IV (INFUSION) 022065 NDA R-Pharm US Operating, LLC 70020-1911 N 70020-1911-1

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;IV (INFUSION)Strength15MG/VIAL
Approval Date:Oct 16, 2007TE:RLD:Yes
Patent:➤ Sign UpPatent Expiration:Jul 23, 2022Product Flag?Substance Flag?Delist Request?Y
Patent:➤ Sign UpPatent Expiration:Jul 23, 2022Product Flag?Substance Flag?Delist Request?Y
Patent:➤ Sign UpPatent Expiration:Nov 26, 2018Product Flag?Substance Flag?Delist Request?Y

Expired US Patents for NDA 022065

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
R-pharm Us Llc IXEMPRA KIT ixabepilone INJECTABLE;IV (INFUSION) 022065-001 Oct 16, 2007 ➤ Sign Up ➤ Sign Up
R-pharm Us Llc IXEMPRA KIT ixabepilone INJECTABLE;IV (INFUSION) 022065-002 Oct 16, 2007 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
UBS
Boehringer Ingelheim
Accenture
Healthtrust
Cantor Fitzgerald
Fish and Richardson
Fuji
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.